Chemicals and pharmaceuticals group DSM booked a lost of €60m in the final quarter of 2009 partly due to pressure from one-off costs.

Turnover was down 4% at €1bn. According to the Financieele Dagblad, turnover excluding acquisitions was down 18%, due to lower volume and lower prices.
‘In what was undoubtedly one of the most challenging years in DSM’s history, we stayed the course and remained fully committed to our customers, innovation and sustainability,’ CEO Feike Sijbesma said in a statement.
The company is not giving a quantative outlook for 2010.